

Title (en)
A METHOD FOR TREATING VIRAL DISEASES AND OTHER DISORDERS BY ALTERING IMMEDIATE GENE EXPRESSION THROUGH ADMINISTRATION OF PEPTIDE T

Title (de)
VERFAHREN ZUR BEHANDLUNG VON VIURUSERKRANKUNGEN UND ANDEREN STÖRUNGEN DURCH VERÄNDERUNG DER "IMMEDIATE GENE EXPRESSION" DURCH VERABREICHUNG VON PEPTID T

Title (fr)
PROCEDE POUR TRAITER DES MALADIES VIRALES ET D'AUTRES TROUBLES PAR LA MODIFICATION DE L'EXPRESSION GENIQUE IMMEDIATE AU MOYEN DE L'ADMINISTRATION DU PEPTIDE T

Publication
EP 1242109 A4 20040602 (EN)

Application
EP 00990995 A 20001109

Priority
• US 0042030 W 20001109
• US 16436399 P 19991109

Abstract (en)
[origin: WO0134095A2] A method for inhibiting viral replication and for treating neurotropic conditions by regulating/inhibiting immediate early gene expression in host cells comprises administering an inhibiting/regulating effective amount of a peptide of formula (I): R<a>-Ser-Thr-Thr-Thr-Asn-Tyr-R where R<a> represents an amino terminal residue Ala- or D- Ala and R represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): R1-R2-R3-R4-R5 where R1 is an amino terminal residue Thr-, Ser-, Asn-, Glu-, Arg-, Ile- or Leu-, R2 is Thr, Ser, or Asp, R3 is Thr, Ser, Asn, Arg, Gln, Lys, or Trp, R4 is Tyr and R5 is preferably a carboxy terminal residue -Thr, -Arg or Gly or a derivative thereof with a corresponding D-amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, in a physiologically suitable carrier.

IPC 1-7
A61K 38/08; A61P 31/12

IPC 8 full level
A61K 38/00 (2006.01); **A61K 38/08** (2019.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **A61P 31/12** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **C07K 7/06** (2006.01)

CPC (source: EP KR US)
A61K 38/00 (2013.01 - KR); **A61K 38/08** (2013.01 - EP US); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)
• [X] EP 0579363 A1 19940119 - ADVANCED PEPTIDES & BIOTECH [US]
• [X] WO 9320102 A1 19931014 - PEPTIDE TECHNOLOGY LTD [AU], et al
• See references of WO 0134095A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0134095 A2 20010517; WO 0134095 A8 20011129; AU 3080001 A 20010606; CA 2389392 A1 20010517; CN 1635913 A 20050706; EP 1242109 A2 20020925; EP 1242109 A4 20040602; IL 149443 A0 20021110; JP 2003528817 A 20030930; KR 20020063182 A 20020801; MX PA02004619 A 20040910; ZA 200203120 B 20021127

DOCDB simple family (application)
US 0042030 W 20001109; AU 3080001 A 20001109; CA 2389392 A 20001109; CN 00815482 A 20001109; EP 00990995 A 20001109; IL 14944300 A 20001109; JP 2001536100 A 20001109; KR 20027006014 A 20020509; MX PA02004619 A 20001109; ZA 200203120 A 20020419